Powerful and novel statistical methods to detect genetic variants associated with or putative causal to Alzheimer’s disease
- PI
- Pan, Wei
- DAR ID
- 10141
- Initial Approval Date
- December 18, 2019
- Current DAR Status
- Active
- PI Institution
- University of Minnesota
- PI Institution Country
- United States
- PI Institution Type
- Non-Profit
Requested Datasets (46)
NG00067Alzheimer's Disease Sequencing Project Umbrella StudyNG00108Profiling microglia expression profiles in AD using single-nuclei RNA-seqNG00113Metabolomic and lipidomic signatures in Alzheimer disease brainsNG00114DNA Methylation in Alzheimer disease brainsNG00119Health and Retirement Study Genotype Data 2006-2012NG00117NCRAD Families GWASNG00127A longitudinal study of Alzheimer's Disease and other dementing illnesses – KnightADRC GWASNG00126A fast and robust strategy to remove variant level artifacts in Alzheimer’s Disease Sequencing Project data (Belloy et al. 2022)NG00130Large scale CSF proteogenomic atlasNG00144The Prediction of Alzheimer’s Disease through Multi-Trait Genetic ModelingNG00131Large scale genetics study on CSF and brain metabolite levelsNG00102Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders
Show more
NG00160Sex-specific genetic architecture of late-life memory performanceNG00022ADC1 - Alzheimer's Disease Center Dataset 1NG00023ADC2 - Alzheimer's Disease Center Dataset 2NG00024ADC3 - Alzheimer's Disease Center Dataset 3NG00068ADC4 - Alzheimer's Disease Center Dataset 4NG00069ADC5 - Alzheimer's Disease Center Dataset 5NG00070ADC6 - Alzheimer's Disease Center Dataset 6NG00071ADC7 - Alzheimer's Disease Center Dataset 7NG00136ADC8 - Alzheimer's Disease Center Dataset 8NG00137ADC9 - Alzheimer's Disease Center Dataset 9NG00138ADC10 - Alzheimer's Disease Center Dataset 10NG00139ADC11 - Alzheimer's Disease Center Dataset 11NG00140ADC12 - Alzheimer's Disease Center Dataset 12NG00149ADC13 - Alzheimer's Disease Center Dataset 13NG00150ADC14 - Alzheimer's Disease Center Dataset 14NG00151ADC15 - Alzheimer's Disease Center Dataset 15NG00159Longitudinal Change in Memory Performance as a Strong Endophenotype for Alzheimer’s Disease – Archer, et al, 2023NG00157Sex-specific genetic predictors of Alzheimer's disease biomarkers – Deming, et al. 2018NG00158Sex differences in the genetic predictors of Alzheimer’s pathology – Dumitrescu, et al. 2019NG00161Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease – Eissman, et al. 2022NG00156Genetic variants and functional pathways associated with resilience to Alzheimer's diseaseNG00142Plasma Cell-Free RNA Transcriptomics for AD and Related DementiasNG00166Association results from the ADSP R3 17k WGS data set - Lee et al., 2023NG00169Progressive Supranuclear Palsy (PSP) Summary Statistics- Farrell et al., 2024NG00141The Sacramento Area Latino Study on AgingNG00172GWAS Summary Statistics of SNVs/INDELs/SVs for Progressive Supranuclear Palsy (PSP) – Wang et al., 2024NG00100Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. Kunkle et al. (2021)NG00177ADGC Multi-Ancestry GWAS Meta-Analysis – Rajabli et al., 2025NG00179AD GWAS in participants of African ancestry – Ray et al., 2024NG00175Genome-wide association study of neuropathology endophenotypesNG00189GWAS summary statistics of neuropsychiatric symptoms in MCI and dementia – Vattathil et al., 2025NG00187Stability of general cognitive ability from infancy to adulthood: A combined twin and genomic investigationNG00186Genetic Component of the Mapping the Human Connectome During Typical Aging (HCP-A) & Vulnerability and Resiliency in the Aging Adult Brain Connectome (AABC)NG00176CNVs from ADSP WES data using CANOES software
Research Use Statement
We have been developing more powerful statistical methods to detect common variant (CV)- or rare variant (RV)-complex trait associations and/or putative causal relationships for GWAS and DNA sequencing data. Here we propose applying our new methods, along with other suitable existing methods, to the existing ADSP sequencing data and other AD GWAS data provided by NIA, hence requesting approval for accessing the ADSP sequencing and other related GWAS/genetic data. We have the following two specific Aims:
Aim1. Association testing under genetic heterogeneity: For complex traits, genetic heterogeneity, especially of RVs, is ubiquitous as well acknowledged in the literature, however there is barely any existing methodology to explicitly account for genetic heterogeneity in association analysis of RVs based on a single sample/cohort. We propose using secondary and other omic data, such as transcriptomic or metabolomic data, to stratify the given sample, then apply a weighted test to the resulting strata, explicitly accounting for genetic heterogeneity that causal RVs may be different (with varying effect sizes) across unknown and hidden subpopulations. Some preliminary analyses have confirmed power gains of the proposed approach over the standard analysis.
Aim 2. Meta analysis of RV tests: Although it has been well appreciated that it is necessary to account for varying association effect sizes and directions in meta analysis of RVs for multi-ethnic cohorts, existing tests are not highly adaptive to varying association patterns across the cohorts and across the RVs, leading to power loss. We propose a highly adaptive test based on a family of SPU tests, which cover many existing meta-analysis tests as special cases. Our preliminary results demonstrated possibly substantial power gains.
Aim 3. Inferring (putative) causal genes/proteins/metabolites for AD. We will apply TWA/PWAS/MWAS/xWAS methods to ADSP, AD GWAS and other omic data to identify (putative) causal genes, proteins, metabolites and other molecular traits for AD. These methods may be based on standard linear models or emerging ML/AI methods.
Aim1. Association testing under genetic heterogeneity: For complex traits, genetic heterogeneity, especially of RVs, is ubiquitous as well acknowledged in the literature, however there is barely any existing methodology to explicitly account for genetic heterogeneity in association analysis of RVs based on a single sample/cohort. We propose using secondary and other omic data, such as transcriptomic or metabolomic data, to stratify the given sample, then apply a weighted test to the resulting strata, explicitly accounting for genetic heterogeneity that causal RVs may be different (with varying effect sizes) across unknown and hidden subpopulations. Some preliminary analyses have confirmed power gains of the proposed approach over the standard analysis.
Aim 2. Meta analysis of RV tests: Although it has been well appreciated that it is necessary to account for varying association effect sizes and directions in meta analysis of RVs for multi-ethnic cohorts, existing tests are not highly adaptive to varying association patterns across the cohorts and across the RVs, leading to power loss. We propose a highly adaptive test based on a family of SPU tests, which cover many existing meta-analysis tests as special cases. Our preliminary results demonstrated possibly substantial power gains.
Aim 3. Inferring (putative) causal genes/proteins/metabolites for AD. We will apply TWA/PWAS/MWAS/xWAS methods to ADSP, AD GWAS and other omic data to identify (putative) causal genes, proteins, metabolites and other molecular traits for AD. These methods may be based on standard linear models or emerging ML/AI methods.
Non-Technical Summary
We propose applying our newly developed statistical and computational methods, along with other suitable existing methods, to the existing ADSP sequencing data, other AD GWAS data and other omic data to detect common or rare genetic variants and other molecular traits, such as genes/proteins/metabolites, associated with and/pr (putative) causal to Alzheimer’s disease (AD). The novelty and power of our new methods are in three aspects: first, we consider and account for possible genetic heterogeneity with several subcategories of AD; second, we apply powerful meta-analysis methods to combine the association analyses across multiple subcategories of AD; third, we will develop and apply standard linear model- and emerging ML/AI-based causal inference methods to infer causal genes, proteins, metabolites and other traits for AD. In addition, our proposed analyses of the existing large amount of ADSP sequencing data and other AD GWAS data with our developed new methods are novel, powerful and cost-effective.
Reported Publications (3)
Publications shown are those reported by investigators through NIAGADS DAR reporting and renewal processes and may not represent a complete list of publications associated with the project.
- Large-Scale Genotype-Based Trait Imputation With Multi-Ancestry GWAS Data. Ren J, et al. Genetic epidemiology. 2026. PMID: 41537459
- Enhancing nonlinear transcriptome- and proteome-wide association studies via trait imputation with applications to Alzheimer's disease. He R, et al. PLoS genetics. 2025. PMID: 40209152
- MATS: a novel multi-ancestry transcriptome-wide association study to account for heterogeneity in the effects of cis-regulated gene expression on complex traits. Knutson KA, et al. Human molecular genetics. 2023. PMID: 36179104